<DOC>
	<DOCNO>NCT00555646</DOCNO>
	<brief_summary>This open label , single center , control study subject 's two treatment plaque area assign investigator 1:1 ( ) PH-10 ambient light exposure ( b ) PH-10 544 nm LED light illumination 10 J/cm2 . A third plaque area receive treatment serve control . Subjects least three distinct , stable study plaque area receive experimental therapy two treatment plaque area twice week ( 2-5 day apart ) less 12 week remission observe treatment plaque area . If remission observe treatment plaque area treatment area discontinue area assess weekly . A third plaque area ( control plaque area ) receive drug light treatment serve internal control . Primary efficacy assess 12 week initial PH-10 treatment . Subjects follow total 16 week allow assessment Durability Response treat lesion comprehensive follow-up adverse event .</brief_summary>
	<brief_title>Topical PH-10 Aqueous Hydrogel Photodynamic Therapy Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Stable , moderate severe plaque psoriasis least three distinct plaque area , separate least 2.5cm band normal skin . Study plaque area , cover contiguous area 15 x 35 cm size , minimum plaque size 2 cm2 . All study plaque area must trunk extremity ( exclude palm , sol , scalp , facial intertriginous site ) . Fitzpatrick skin type IVI . Ability understand sign inform consent document . Female subject childbearing potential pregnant , attempt conceive , nursing infant . Subjects receive PUVA UVB light therapy systemic antipsoriatic therapy within 4 week study treatment ( two week methotrexate ) . Subjects received topical antipsoriatic therapy ( include corticosteroid , tar , anthralin , Vitamin D analog ) study plaque area within 2 week study treatment . Subjects receive photosensitize phototoxic drug within 4 week study treatment . Subjects receive approved biologic drug therapy psoriasis within 3 month 5 halflives study treatment . Subjects participate clinical research study within 4 week study treatment . Subjects history porphyria , systemic lupus erythematosus xeroderma pigmentosum . Subjects clinical condition , opinion Principal Investigator , may pose health risk subject involve study detrimentally affect regular followup subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>